ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

November 1, 2012

Senate Bill Would Prohibit Political Appointments To Advisory Groups

January 9, 1976

Intramural Pis To Control Own Budgets, Have Greater Autonomy, Klausner Says

December 15, 1995

Studies Seek to Identify High-Risk Groups to Justify Mammography Screening at 40

May 4, 2012

RFAs Available

February 23, 1996

DCCP Board Approves Concept Of RFA, New, Competing Contracts

October 15, 1982